Last reviewed · How we verify
Split-dose full-volume PEG
Split-dose full-volume PEG, marketed by Kyunghee University Medical Center, holds a position in the bowel preparation market for colonoscopy procedures. The drug's key strength lies in its key composition patent, which is set to expire in 2028, providing a period of market exclusivity. The primary risk is the potential increase in competition following the patent expiry, which could impact market share and revenue.
At a glance
| Generic name | Split-dose full-volume PEG |
|---|---|
| Sponsor | Kyunghee University Medical Center |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Can Artificial Intelligence Reduce Consumption of Standard High Volume Bowel Preparation Regimen Among Older Population, Without Compromising the Quality of Colonoscopy? An International Multi-centre Randomized Controlled Trial. (NA)
- Bowel Preparation for Colonoscopy in the Elderly (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Split-dose full-volume PEG CI brief — competitive landscape report
- Split-dose full-volume PEG updates RSS · CI watch RSS
- Kyunghee University Medical Center portfolio CI